Her main research concerns Immunology, Chronic lymphocytic leukemia, Internal medicine, Leukemia and Cancer research. Her Immunology study frequently links to other fields, such as Risk factor. Her Chronic lymphocytic leukemia research includes elements of Cyclophosphamide, Disease, Bone marrow and Gene expression profiling.
Her research in Internal medicine intersects with topics in Gastroenterology and Oncology. Her Leukemia study combines topics in areas such as Monoclonal B-cell lymphocytosis and Monoclonal. In her research on the topic of Cancer research, Osteoclast is strongly related with Multiple myeloma.
Her scientific interests lie mostly in Immunology, Chronic lymphocytic leukemia, Internal medicine, Cancer research and Molecular biology. Chronic lymphocytic leukemia is a subfield of Leukemia that Diane F. Jelinek investigates. Her Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Oncology.
Her work in Cancer research tackles topics such as Multiple myeloma which are related to areas like Endocrinology. The study incorporates disciplines such as Cell culture, Antibody, Cellular differentiation and Biochemistry in addition to Molecular biology. Her B-cell activating factor research integrates issues from Receptor and Receptor expression.
Diane F. Jelinek focuses on Chronic lymphocytic leukemia, Immunology, Internal medicine, Antibody and Oncology. Chronic lymphocytic leukemia is a subfield of Leukemia that Diane F. Jelinek tackles. Her Immunology study combines topics from a wide range of disciplines, such as Cancer and Gene.
In her work, Stage is strongly intertwined with Gastroenterology, which is a subfield of Internal medicine. Her research investigates the connection between Antibody and topics such as Molecular biology that intersect with problems in Amyloid and Proteogenomics. Her research in Immunoglobulin light chain focuses on subjects like Multiple myeloma, which are connected to Monoclonal, Pathology, Cell culture and Bone marrow.
Her primary areas of study are Antibody, Molecular biology, Immunology, Internal medicine and Chronic lymphocytic leukemia. Her work on Hypergammaglobulinemia is typically connected to Kappa, Molecular mass and Lambda as part of general Antibody study, connecting several disciplines of science. Her studies examine the connections between Molecular biology and genetics, as well as such issues in Immunoglobulin light chain, with regards to Polyclonal antibodies, Proteogenomics and Mass spectrometry.
Her Immunology study frequently draws connections to other fields, such as Cancer. Her Internal medicine study deals with Oncology intersecting with Hematology and Cohort. Her Chronic lymphocytic leukemia research includes themes of Gastroenterology, Immunoglobulin G and Retrospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
Robert A. Kyle;Ellen D. Remstein;Terry M. Therneau;Angela Dispenzieri.
The New England Journal of Medicine (2007)
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
Anne J. Novak;Anne J. Novak;Jaime R. Darce;Jaime R. Darce;Bonnie K. Arendt;Bonnie K. Arendt;Brandon Harder;Brandon Harder.
Cloning and regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis.
Diane F. Jelinek;Stefan Andersson;Clive A. Slaughter;David W. Russell.
Journal of Biological Chemistry (1990)
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Angela Dispenzieri;Robert A. Kyle;Jerry A. Katzmann;Terry M. Therneau.
Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997
Michael R. Grever;David M. Lucas;Gordon W. Dewald;Donna S. Neuberg.
Journal of Clinical Oncology (2007)
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Tait D. Shanafelt;Xin V. Wang;Neil E. Kay;Curtis A. Hanson.
The New England Journal of Medicine (2019)
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Neil E. Kay;Susan M. Geyer;Timothy G. Call;Tait D. Shanafelt.
Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia
Tait D. Shanafelt;Thomas E. Witzig;Stephanie R. Fink;Robert B. Jenkins.
Journal of Clinical Oncology (2006)
Regulated Expression of BAFF-Binding Receptors during Human B Cell Differentiation
Jaime R. Darce;Bonnie K. Arendt;Xiaosheng Wu;Diane F. Jelinek.
Journal of Immunology (2007)
Chronic Lymphocytic Leukemia
Neil E. Kay;Terry J. Hamblin;Diane F. Jelinek;Gordon W. Dewald.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: